iTEAR®100 Commercialization
Dry Eye Disease
CommercialActive
Key Facts
About Olympic Ophthalmics
Olympic Ophthalmics is a commercial-stage private company that has developed and launched the iTEAR®100, a novel, drug-free medical device for dry eye disease. The device represents a unique neuromodulation approach in a market dominated by pharmaceuticals and lubricants, offering a potential long-term management solution. The company leverages a prescription-based, direct-to-patient sales model supported by telehealth services. Its leadership includes experienced medical device investors and executives, positioning it to capture share in the large and growing dry eye market.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Elate Ocular® | Cambium Bio | Phase 3 |
| OT-301 | Ocumension Therapeutics | Phase 2 |
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| Tivanisiran | Sylentis | Phase 2/3 |
| A197 | Aramis Biosciences | Phase 2 |
| KM102 | Theratome Bio | Pre-clinical |
| HydraD | EyeD Pharma | Pre-Clinical |
| ST-100 (Vezocolmitide) | Stuart Therapeutics | Phase 3 |
| BRM421 | BRIM Biotechnology | Phase 3 |